Roy Midhun K, Kuriakose Abaedha Susan, Varma Sujith K, Jacob Lejo A, Beegum N Jeena
Department of Pharmacy Practice, National College of Pharmacy, Kozhikode, Kerala, India.
Department of Pharmaceutics, National College of Pharmacy, Manassery, Kozhikode, India.
Diabetes Metab Syndr. 2017 Jan-Mar;11(1):31-35. doi: 10.1016/j.dsx.2016.07.003. Epub 2016 Jul 27.
The study was designed for comparing the efficacy and cost effectiveness of Pregabalin and Duloxetine used in Diabetic Neuropathic Pain.
The prospective interventional 6 month study was conducted in a diabetic clinic of a 500 bedded tertiary care hospital in South India. The subjects having diagnosed with diabetic neuropathy and not treated with Pregabalin and Duloxetine or any other drugs of its class were selected. The data were collected using NPS and Neuro QoL questionnaires. The cost of both drugs used in the study was calculated as the mean of the price of 3 leading common brands of those drugs. The comparative efficacy was calculated by comparing the mean difference produced by both drugs in NPS and QoL scores. The cost effectiveness were calculated by ICER ratio.
The results have shown a significant improvement in the mean difference of NPS and Neuro QoL scores of both Pregabalin (p=<0.001) and Duloxetine (p=<0.001) before and after the therapy, the Duloxetine dominates over Pregabalin in both. The mean cost of Pregabalin for 3 months therapy was found to be INR 668.7 and that for Duloxetine was INR 756. Duloxetine showed a better effect but more expensive. ICER ratio was calculated and found that a cost of INR 61.47 per extra QoL gained by Duloxetine.
The study have revealed that, both drugs are found to be effective.On conducting cost effective analysis, a significant better improvement in QoL of patients was obtained by Duloxetine with comparatively mild increase in the price.
本研究旨在比较普瑞巴林和度洛西汀用于糖尿病性神经病理性疼痛的疗效和成本效益。
在印度南部一家拥有500张床位的三级护理医院的糖尿病诊所进行了为期6个月的前瞻性干预研究。选取已诊断为糖尿病神经病变且未接受过普瑞巴林、度洛西汀或同类其他药物治疗的受试者。使用NPS和Neuro QoL问卷收集数据。研究中使用的两种药物的成本计算为这两种药物的3个主要常见品牌价格的平均值。通过比较两种药物在NPS和QoL评分中产生的平均差异来计算比较疗效。通过ICER比率计算成本效益。
结果显示，治疗前后普瑞巴林（p =<0.001）和度洛西汀（p =<0.001）的NPS和Neuro QoL评分的平均差异均有显著改善，度洛西汀在两者中均优于普瑞巴林。发现普瑞巴林3个月治疗的平均成本为668.7印度卢比，度洛西汀为756印度卢比。度洛西汀效果更好但更昂贵。计算了ICER比率，发现度洛西汀每增加一个QoL的成本为61.47印度卢比。
研究表明，两种药物均有效。在进行成本效益分析时，度洛西汀使患者的QoL有显著更好的改善，而价格相对温和上涨。
